Munich Leukemia Laboratory Selects IBM Watson and Illumina for Research Collaboration to Advance Diagnostics and Develop Personalized Treatment Tools for Leukemia & Lymphoma

IBMMunich Leukemia Laboratory (MLL), a state-of-the-art leukemia and lymphoma diagnostic and research laboratory based in Munich, has teamed up with IBM (NYSE: IBM) and Illumina, Inc. (NASDAQ: ILMN) to help build a new cognitive technology prototype that aims to help researchers improve leukemia treatment.

The prevalence of leukemia is on the rise in Europe, with 15,000 new diagnoses each year in Germany alone.(1) MLL will use NovaSeq technology from Illumina, the global leader in next-generation sequencing technology, to sequence samples from its biobank of more than 500,000 cases. MLL researchers then plan to use Watson to help analyze the genomic data alongside other data sources. The project intends to include innovative testing processes such as automated phenotyping and genotyping including whole genome sequencing (WGS) and transcriptome sequencing (RNASeq) in 5,000 cases.

The ultimate goal is to develop a Watson-based technology prototype that can help analyze genomic and phenotypic data alongside medical literature, guidelines and study results, providing clinicians with information relevant to leukemia care. Following successful development, the tool could also be made available to other laboratories in the future.

Prof. Torsten Haferlach, co-founder and CEO of MLL, states, "We at MLL are excited to combine our data and knowledge, IBM's cognitive computing tools, and Illumina's new sequencing platform to create a new era of insights in leukemia biology that will also drive more personalized treatment strategies."

"As a company committed to improving human health, we are delighted to welcome MLL as our first European customer to adopt the NovaSeq platform," said Paula Dowdy, Senior Vice President and General Manager, Illumina, Europe, Middle East, and Africa. "MLL's strategic decision to create a future path for whole-genome sequencing to help promote better health outcomes, reflects one of Illumina’s key strategies to connect genomics to the everyday lives of those living with cancer."

MLL will utilize Illumina's BaseSpace® Informatics Suite to be able to streamline data analysis, storage, data curation and aggregation. The BaseSpace Sequence Hub Frankfurt site will help MLL manage the data as the project scales and facilitates data transfer to IBM Watson. Additional tertiary analysis with BaseSpace Cohort Analyzer and BaseSpace Correlation Engine allows MLL's genomic data to be combined with other clinical data to enhance interpretation results.

"Cognitive computing is critical to help providers unlock the insights hidden in large data pools and scale their expertise in a global market through digital services," said Bart de Witte, director of digital health, IBM. "This research collaboration is indicative of the growing global market to create and implement new cognitive approaches to data-driven challenges for health systems that are increasingly overwhelmed by data."

About MLL
The Munich Leukemia Laboratory was founded in 2005 to take diagnostic responsibility for patients with leukemia and lymphoma for both in-patient and out-patient settings. The team of 150 hematologists, researchers and technicians works to optimize and refine diagnostics, including automation of laboratory procedures and improvements according to the established norms of EN ISO 15189 as well as national and international involvement in scientific projects and research trials. MLL is committed to expanding and improving high-quality diagnostics of hematological neoplasms, at the highest scientific and technical levels.

About IBM
IBM Watson is the first commercially available cognitive computing capability representing a new era in computing. The system, delivered through the cloud, analyzes high volumes of data, understands complex questions posed in natural language, and proposes evidence-based answers. Watson continuously learns, gaining in value and knowledge over time, from previous interactions. The IBM Watson Health unit helps improve the ability of doctors, researchers and insurers to innovate by surfacing insights from the massive amount of personal health data being created and shared daily.

About Illumina, Inc.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

1. European Leukemia Network.

Most Popular Now

Which Self-Help Websites Actually Improv…

From depression to weight loss, insomnia to cutting back on alcohol or cigarettes, the Internet teems with sites that promise to help people improve their health. Which of these really...

Read more

Facial Recognition Software Helps Diagno…

Researchers with the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, and their collaborators, have successfully used facial recognition software to diagnose a rare, genetic...

Read more

AbedGraham and Highland Marketing Partne…

Global efforts to enhance clinical engagement and accelerate the impact of digital technology in improving patient care, will be boosted by a new bilateral relationship between two organisations dedicated to...

Read more

eHealth Hub: Call for the First Lean Sta…

The Lean Startup Academy is an unique opportunity to mature your business by systematically testing your ideas against the market with the support of experts. The course will help you...

Read more

Medtec Europe 2017: Discover the Latest …

4 - 6 April 2017, Stuttgart, Germany. Medtec Europe will once again provide over 7,000 attendees and more than 600 exhibitors from 70 countries the opportunity to share, learn, and discover...

Read more

Highland Marketing Recruits Strategy and…

PR and marketing agency Highland Marketing has appointed Lyn Whitfield to the new post of strategy and content director. Whitfield is a journalist by background, who has specialised in writing...

Read more

The Grants4Apps® Accelerator Berlin 2017

The Grants4Apps® Accelerator is a mentoring program for digital health startups taking place in Berlin. This year's batch with five startups runs from September until November. The program offers mentoring...

Read more

Philips and PathAI Team Up to Improve Br…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and PathAI, a company that develops artificial intelligence technology for pathology, are collaborating with the aim to develop...

Read more

Health 2.0 Europe 2017

3 - 5 May 2017, Barcelona, Spain. The 8th edition of Health 2.0 Europe will take place in Barcelona in a new location: Fira Montjuic, Plaza España. Health 2.0 Europe will...

Read more

Biased Bots: Human Prejudices Sneak into…

In debates over the future of artificial intelligence, many experts think of the new systems as coldly logical and objectively rational. But in a new study, researchers have demonstrated how...

Read more

Allscripts Announces dbMotionTM Solution…

Allscripts (NASDAQ:MDRX) announced today that its Community interoperability platform, dbMotion Solution, is now available through the cloud via Microsoft Azure. The cloud-based solution offers the same capabilities as the on-premise...

Read more

Public Funding Essential for Advances in…

In the budget President Trump recently submitted to Congress, he asked for a reduction in the 2018 funding of the U.S. National Institutes of Health (NIH) of almost 20 percent...

Read more
(HEALTH IT) SPACE - Take a look at who has just Joined